Sanofi Recalls 2.8M Allergy Injectors

Oct 30, 2015

Sanofi is voluntarily recalling all 2.8 million of its Auvi-Q epinephrine injectors from the U.S. and Canada.

The products have been found to potentially have inaccurate dosage delivery. The recall involves all Auvi-Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers, and consumers.

The injectors are used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for, or have a history of these reactions.

Mylan, which makes rival product, EpiPen, has quickly confirmed it has sufficient supply of its auto-injector to meet any anticipated demand.

Read the Sanofi press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments